DEFENCE'S CHIEF SCIENTIFIC OFFICER DR. MOUTIH RAFEI DISCUSSES THE ACCUM
PLATFORM FOR CANCER TREATMENTS ON MONEY TALK RADIO WITH ELLIS MARTIN

EQS-News: Defence Therapeutics Inc. / Key word(s): Miscellaneous
DEFENCE'S CHIEF SCIENTIFIC OFFICER DR. MOUTIH RAFEI DISCUSSES THE ACCUM
PLATFORM FOR CANCER TREATMENTS ON MONEY TALK RADIO WITH ELLIS MARTIN

17.06.2024 / 08:00 CET/CEST
The issuer is solely responsible for the content of this announcement.

---------------------------------------------------------------------------

_________________________________________________________________

CSE: DTC FSE: DTC USOTC: DTCFF PRESS RELEASE

DEFENCE'S CHIEF SCIENTIFIC OFFICER DR. MOUTIH RAFEI DISCUSSES THE ACCUM
PLATFORM FOR CANCER TREATMENTS ON MONEY TALK RADIO WITH ELLIS MARTIN

Vancouver, BC, Canada, June 17th, 2024 - Defence Therapeutics Inc.
("Defence" or the "Company"), (CSE: DTC, OTCQB: DTCFF, FSE: DTC), a Canadian
biopharmaceutical company developing novel immune-oncology vaccines and drug
delivery technologies, is please to share the interview of Dr. Moutih Rafei,
Defence's Chief Scientific Officer, with Ellis Martin on Money Talk Radio.


To Listen to the Interview, please visit:

https://www.abnnewswire.net/lnk/7D1OV2C6

About The Ellis Martin Report:

The Ellis Martin Report (TEMR) is an internet based radio program showcasing
potentially undervalued companies to an audience of potential retail
investors and fund managers that comprise its listening audience. TEMR is
broadcasted on the VoiceAmerica Business Channel and The Opportunity Radio
Network. CEO and company interviews are paid for by those represented on the
program.

About Defence:

Defence Therapeutics is a publicly-traded clinical-stage biotechnology
company working on engineering the next generation vaccines and ADC products
using its proprietary platform. The core of Defence Therapeutics platform is
the ACCUM® technology, which enables precision delivery of vaccine antigens
or ADCs in their intact form to target cells. As a result, increased
efficacy and potency can be reached against catastrophic illness such as
cancer and infectious diseases.

For further information:

Sebastien Plouffe, President, CEO and Director

P: (514) 947-2272

Splouffe@defencetherapeutics.com

www.defencetherapeutics.com

Cautionary Statement Regarding "Forward-Looking" Information

This release includes certain statements that may be deemed "forward-looking
statements". All statements in this release, other than statements of
historical facts, that address events or developments that the Company
expects to occur, are forward-looking statements. Forward-looking statements
are statements that are not historical facts and are generally, but not
always, identified by the words "expects", "plans", "anticipates",
"believes", "intends", "estimates", "projects", "potential" and similar
expressions, or that events or conditions "will", "would", "may", "could" or
"should" occur. Although the Company believes the expectations expressed in
such forward-looking statements are based on reasonable assumptions, such
statements are not guarantees of future performance and actual results may
differ materially from those in the forward-looking statements. Factors that
could cause the actual results to differ materially from those in
forward-looking statements include regulatory actions, market prices, and
continued availability of capital and financing, and general economic,
market or business conditions. Investors are cautioned that any such
statements are not guarantees of future performance and actual results or
developments may differ materially from those projected in the
forward-looking statements. Forward-looking statements are based on the
beliefs, estimates and opinions of the Company's management on the date the
statements are made. Except as required by applicable securities laws, the
Company undertakes no obligation to update these forward-looking statements
in the event that management's beliefs, estimates or opinions, or other
factors, should change.

Neither the CSE nor its market regulator, as that term is defined in the
policies of the CSE, accepts responsibility for the adequacy or accuracy of
this release.


---------------------------------------------------------------------------

17.06.2024 CET/CEST Dissemination of a Corporate News, transmitted by EQS
News - a service of EQS Group AG.
The issuer is solely responsible for the content of this announcement.

The EQS Distribution Services include Regulatory Announcements,
Financial/Corporate News and Press Releases.
Archive at www.eqs-news.com

---------------------------------------------------------------------------

   Language:       English
   Company:        Defence Therapeutics Inc.
                   1680 - 200 Burrard St
                   V6C3L6 Vancouver
                   Canada
   E-mail:         info@defencetherapeutics.com
   Internet:       https://defencetherapeutics.com
   ISIN:           CA24463V1013
   WKN:            A3CN14
   Listed:         Regulated Unofficial Market in Frankfurt, Stuttgart;
                   Toronto
   EQS News ID:    1926001

End of News EQS News Service
---------------------------------------------------------------------------

1926001 17.06.2024 CET/CEST